Gliomas - An experience based on molecular markers

Impact of Molecular Markers on Personalised-Treatment Concepts in Gliomas

Molecular pathology in adult gliomas: diagnostic, prognostic, and predictive markers.

Over the past 10 years, there has been an increasing use of molecular markers in the assessment and management of adult malignant gliomas. Some molecular signatures are used diagnostically to help pathologists classify tumours, whereas others are used to estimate prognosis for patients. Most crucial, however, are those markers that are used to predict response to certain therapies, thereby dire...

Management of Gliomas: Relevance of Molecular Markers for Clinical Practice

Molecular markers in low-grade gliomas: predictive or prognostic?

PURPOSE To investigate whether TP53 mutation, 1p/19q codeletions, O(6)-methylguanylmethyltransferase (MGMT) promoter methylation, and isocitrate dehydrogenase 1 (IDH1) mutation predict natural course of disease or response to radiotherapy or chemotherapy or both in low-grade glioma patients. EXPERIMENTAL DESIGN Cohort A consisted of 89 patients with diffuse astrocytoma World Health Organizati...

Diagnostic, prognostic and predictive relevance of molecular markers in gliomas.

The advances of genome-wide 'discovery platforms' and the increasing affordability of the analysis of significant sample sizes have led to the identification of novel mutations in brain tumours that became diagnostically and prognostically relevant. The development of mutation-specific antibodies has facilitated the introduction of these convenient biomarkers into most neuropathology laboratori...